Skip to content

Advertisement

BMC Cancer

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)

  • Florian Huemer1, 2, 3,
  • Josef Thaler4,
  • Gudrun Piringer4,
  • Hubert Hackl5,
  • Lisa Pleyer1, 2, 3,
  • Clemens Hufnagl1, 2, 3,
  • Lukas Weiss1, 2, 3 and
  • Richard Greil1, 2, 3Email author
Contributed equally
BMC Cancer201818:11

https://doi.org/10.1186/s12885-017-3955-4

Received: 15 April 2017

Accepted: 21 December 2017

Published: 3 January 2018

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
15 Apr 2017 Submitted Original manuscript
18 Jun 2017 Reviewed Reviewer Report - david tougeron
21 Aug 2017 Reviewed Reviewer Report - Hans Prenen
29 Aug 2017 Reviewed Reviewer Report - Luciano Cascione
29 Sep 2017 Author responded Author comments - Florian Huemer
Resubmission - Version 2
29 Sep 2017 Submitted Manuscript version 2
2 Oct 2017 Reviewed Reviewer Report - Hans Prenen
1 Dec 2017 Author responded Author comments - Florian Huemer
Resubmission - Version 3
1 Dec 2017 Submitted Manuscript version 3
15 Dec 2017 Reviewed Reviewer Report - Hans Prenen
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
21 Dec 2017 Editorially accepted
3 Jan 2018 Article published 10.1186/s12885-017-3955-4

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
IIIrd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectious Diseases and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria
(2)
Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg, Austria
(3)
Cancer Cluster Salzburg, Salzburg, Austria
(4)
Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria
(5)
Division of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria

Advertisement